Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 40 |
List of Tables | 36 | 5 |
List of Figures | 41 | 1 |
Introduction | 42 | 1 |
Global Markets Direct Report Coverage | 42 | 1 |
Head And Neck Cancer Overview | 43 | 1 |
Therapeutics Development | 44 | 2 |
Pipeline Products for Head And Neck Cancer Overview | 44 | 1 |
Pipeline Products for Head And Neck Cancer Comparative Analysis | 45 | 1 |
Head And Neck Cancer Therapeutics under Development by Companies | 46 | 14 |
Head And Neck Cancer Therapeutics under Investigation by Universities/Institutes | 60 | 2 |
Head And Neck Cancer Pipeline Products Glance | 62 | 4 |
Late Stage Products | 62 | 1 |
Clinical Stage Products | 63 | 1 |
Early Stage Products | 64 | 1 |
Unknown Stage Products | 65 | 1 |
Head And Neck Cancer Products under Development by Companies | 66 | 21 |
Head And Neck Cancer Products under Investigation by Universities/Institutes | 87 | 3 |
Head And Neck Cancer Companies Involved in Therapeutics Development | 90 | 168 |
3SBio Inc. | 90 | 1 |
4SC AG | 91 | 1 |
AB Science SA | 92 | 1 |
AbbVie Inc | 93 | 1 |
Accelerated Pharma, Inc. | 94 | 1 |
Acceleron Pharma, Inc. | 95 | 1 |
Adaptimmune Therapeutics Plc | 96 | 1 |
Aduro BioTech, Inc. | 97 | 1 |
Advaxis, Inc. | 98 | 1 |
Advenchen Laboratories, LLC | 99 | 1 |
Affimed GmbH | 100 | 1 |
Alchemia Limited | 101 | 1 |
Altor BioScience Corporation | 102 | 1 |
Ambrx, Inc. | 103 | 1 |
Amgen Inc. | 104 | 1 |
arGEN-X BV | 105 | 1 |
ArQule, Inc. | 106 | 1 |
Aspyrian Therapeutics, Inc. | 107 | 1 |
Astellas Pharma Inc. | 108 | 1 |
AstraZeneca Plc | 109 | 1 |
Atara Biotherapeutics, Inc. | 110 | 1 |
ATLAB Pharma SAS | 111 | 1 |
Aura Biosciences, Inc. | 112 | 1 |
AVEO Pharmaceuticals, Inc. | 113 | 1 |
Bayer AG | 114 | 1 |
Betta Pharmaceuticals Co. Ltd. | 115 | 1 |
Bexion Pharmaceuticals, LLC | 116 | 1 |
Bio-Path Holdings, Inc. | 117 | 1 |
BioDiem Ltd | 118 | 1 |
Biomics Biotechnologies Co., Ltd. | 119 | 1 |
Bionovis SA | 120 | 1 |
BioNTech AG | 121 | 1 |
Biotest AG | 122 | 1 |
Boehringer Ingelheim GmbH | 123 | 1 |
Boston Biomedical, Inc. | 124 | 1 |
Bristol-Myers Squibb Company | 125 | 1 |
Calithera Biosciences, Inc. | 126 | 1 |
CEL-SCI Corporation | 127 | 1 |
Celgene Corporation | 128 | 1 |
Cell Medica Limited | 129 | 1 |
Cellceutix Corporation | 130 | 1 |
Celldex Therapeutics, Inc. | 131 | 1 |
Celprogen, Inc. | 132 | 1 |
Centrose LLC | 133 | 1 |
Corvus Pharmaceuticals, Inc. | 134 | 1 |
Cristal Therapeutics B.V. | 135 | 1 |
Critical Outcome Technologies Inc. | 136 | 1 |
CTI BioPharma Corp. | 137 | 1 |
Daiichi Sankyo Company, Limited | 138 | 1 |
DNJ Pharma, Inc. | 139 | 1 |
Eisai Co., Ltd. | 140 | 1 |
Eleven Biotherapeutics Inc. | 141 | 1 |
Eli Lilly and Company | 142 | 1 |
EntreChem, S.L. | 143 | 1 |
Etubics Corporation | 144 | 1 |
Eureka Therapeutics, Inc. | 145 | 1 |
F. Hoffmann-La Roche Ltd. | 146 | 1 |
Five Prime Therapeutics, Inc. | 147 | 1 |
G&E Herbal Biotechnology Co., Ltd. | 148 | 1 |
Genelux Corporation | 149 | 1 |
GeneSegues Inc | 150 | 1 |
Genexine, Inc. | 151 | 1 |
Genmab A/S | 152 | 1 |
Genticel S.A. | 153 | 1 |
GlaxoSmithKline Plc | 154 | 1 |
Gliknik, Inc. | 155 | 1 |
Glycotope GmbH | 156 | 1 |
Hanmi Pharmaceuticals, Co. Ltd. | 157 | 1 |
Hookipa Biotech AG | 158 | 1 |
Horizon Pharma Plc | 159 | 1 |
Hutchison MediPharma Limited | 160 | 1 |
Ignyta, Inc. | 161 | 1 |
Immunomedics, Inc. | 162 | 1 |
Immunovaccine, Inc. | 163 | 1 |
Immunovative Therapies, Ltd. | 164 | 1 |
Incuron, LLC | 165 | 1 |
Incyte Corporation | 166 | 1 |
Infinity Pharmaceuticals, Inc. | 167 | 1 |
Innate Pharma S.A. | 168 | 1 |
Inovio Pharmaceuticals, Inc. | 169 | 1 |
InteRNA Technologies B.V. | 170 | 1 |
IRX Therapeutics, Inc. | 171 | 1 |
ISA Pharmaceuticals B.V. | 172 | 1 |
Jiangsu Kanion Pharmaceutical Co., Ltd. | 173 | 1 |
Johnson &Johnson | 174 | 1 |
Kite Pharma Inc | 175 | 1 |
Kolltan Pharmaceuticals, Inc. | 176 | 1 |
Kura Oncology, Inc. | 177 | 1 |
Laboratoires Pierre Fabre SA | 178 | 1 |
Lakewood-Amedex Inc | 179 | 1 |
Loxo Oncology, Inc. | 180 | 1 |
Lytix Biopharma AS | 181 | 1 |
Mabion SA | 182 | 1 |
Mabtech Limited | 183 | 1 |
MacroGenics, Inc. | 184 | 1 |
Marsala Biotech Inc. | 185 | 1 |
Mateon Therapeutics Inc | 186 | 1 |
MaxiVAX SA | 187 | 1 |
Meabco A/S | 188 | 1 |
MedImmune, LLC | 189 | 1 |
Merck &Co., Inc. | 190 | 1 |
Merck KGaA | 191 | 1 |
Merrimack Pharmaceuticals, Inc. | 192 | 1 |
Millennium Pharmaceuticals Inc | 193 | 1 |
Mirati Therapeutics Inc. | 194 | 1 |
Molecular Partners AG | 195 | 1 |
Moleculin Biotech Inc | 196 | 1 |
Molplex Ltd. | 197 | 1 |
NanoCarrier Co., Ltd. | 198 | 1 |
Natco Pharma Limited | 199 | 1 |
Neonc Technologies Inc | 200 | 1 |
Northwest Biotherapeutics, Inc. | 201 | 1 |
Novartis AG | 202 | 1 |
Omnitura Therapeutics Inc. | 203 | 1 |
Oncobiologics, Inc. | 204 | 1 |
Oncolys BioPharma Inc | 205 | 1 |
Oncolytics Biotech Inc. | 206 | 1 |
Onconova Therapeutics, Inc. | 207 | 1 |
OncoSec Medical Incorporated | 208 | 1 |
Ono Pharmaceutical Co., Ltd. | 209 | 1 |
Oryx GmbH &Co. KG | 210 | 1 |
Panacea Biotec Limited | 211 | 1 |
PCI Biotech Holding ASA | 212 | 1 |
PDS Biotechnology Corporation | 213 | 1 |
Pfizer Inc. | 214 | 1 |
Pharma Mar, S.A. | 215 | 1 |
Pique Therapeutics | 216 | 1 |
PlantForm Corporation | 217 | 1 |
Plexxikon Inc. | 218 | 1 |
PNP Therapeutics, Inc. | 219 | 1 |
Profectus BioSciences, Inc. | 220 | 1 |
ProNAi Therapeutics, Inc. | 221 | 1 |
Provectus Biopharmaceuticals, Inc. | 222 | 1 |
R-Pharm | 223 | 1 |
Redx Pharma Plc | 224 | 1 |
Reliance Life Sciences Pvt. Ltd. | 225 | 1 |
Sanofi | 226 | 1 |
Sapvax | 227 | 1 |
Sareum Holdings Plc | 228 | 1 |
Selecta Biosciences, Inc. | 229 | 1 |
Shanghai Henlius Biotech Co., Ltd. | 230 | 1 |
Shenzen SiBiono GeneTech Co., Ltd. | 231 | 1 |
Shionogi &Co., Ltd. | 232 | 1 |
Silence Therapeutics Plc | 233 | 1 |
Sillajen Biotherapeutics | 234 | 1 |
Sinil Pharmaceutical Co., Ltd | 235 | 1 |
SuviCa Inc. | 236 | 1 |
Symphogen A/S | 237 | 1 |
SynCore Biotechnology Co., Ltd. | 238 | 1 |
Taiwan Liposome Company, Ltd. | 239 | 1 |
Takara Bio Inc. | 240 | 1 |
Takis S.r.l. | 241 | 1 |
Tara Immuno-Oncology Therapeutics LLC | 242 | 1 |
Tessa Therapeutics Pte Ltd | 243 | 1 |
Theravectys SA | 244 | 1 |
Tolero Pharmaceuticals, Inc. | 245 | 1 |
TyrNovo Ltd. | 246 | 1 |
UbiVac, LLC | 247 | 1 |
Vaccibody AS | 248 | 1 |
VasGene Therapeutics, Inc. | 249 | 1 |
Vault Pharma Inc. | 250 | 1 |
Vaxeal Holding SA | 251 | 1 |
VentiRx Pharmaceuticals, Inc. | 252 | 1 |
Virttu Biologics Limited | 253 | 1 |
VLPbio | 254 | 1 |
VM Discovery, Inc. | 255 | 1 |
Vyriad Inc | 256 | 1 |
Yabao Pharmaceutical Group Co., Ltd. | 257 | 1 |
Head And Neck Cancer Therapeutics Assessment | 258 | 35 |
Assessment by Monotherapy Products | 258 | 1 |
Assessment by Combination Products | 259 | 1 |
Assessment by Target | 260 | 14 |
Assessment by Mechanism of Action | 274 | 15 |
Assessment by Route of Administration | 289 | 2 |
Assessment by Molecule Type | 291 | 2 |
Drug Profiles | 293 | 821 |
4SC-205 Drug Profile | 293 | 2 |
ABBV-221 Drug Profile | 295 | 1 |
acalabrutinib Drug Profile | 296 | 3 |
AdIL-24 Drug Profile | 299 | 2 |
ADUS-100 Drug Profile | 301 | 3 |
afatinib dimaleate Drug Profile | 304 | 13 |
AFM-22 Drug Profile | 317 | 1 |
AFM-24 Drug Profile | 318 | 1 |
AlloVax Drug Profile | 319 | 2 |
alpelisib Drug Profile | 321 | 3 |
ALT-803 Drug Profile | 324 | 3 |
amcasertib Drug Profile | 327 | 2 |
AMG-319 Drug Profile | 329 | 2 |
Antibodies to Inhibit FRMD4A for Oncology Drug Profile | 331 | 1 |
Antisense Oligonucleotide to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma Drug Profile | 332 | 1 |
Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer Drug Profile | 333 | 1 |
Antisense RNAi Oligonucleotide to Inhibit Mutated Ataxia Telangiectasia Gene for Head and Neck Cancer Drug Profile | 334 | 1 |
apatinib Drug Profile | 335 | 3 |
ARGX-110 Drug Profile | 338 | 4 |
atezolizumab Drug Profile | 342 | 14 |
ATL-101 Drug Profile | 356 | 2 |
Atu-027 Drug Profile | 358 | 4 |
AV-203 Drug Profile | 362 | 3 |
avelumab Drug Profile | 365 | 5 |
axalimogene filolisbac Drug Profile | 370 | 16 |
AY-4 Drug Profile | 386 | 1 |
azacitidine Drug Profile | 387 | 5 |
AZD-1775 Drug Profile | 392 | 3 |
AZD-6738 Drug Profile | 395 | 1 |
AZD-9150 Drug Profile | 396 | 3 |
baltaleucel-T Drug Profile | 399 | 2 |
BAY-1163877 Drug Profile | 401 | 1 |
BB-002 Drug Profile | 402 | 1 |
Biologic for Oncology Drug Profile | 403 | 1 |
BMS-986016 Drug Profile | 404 | 2 |
BMX-001 Drug Profile | 406 | 1 |
BNV-003 Drug Profile | 407 | 1 |
BP-1001 Drug Profile | 408 | 6 |
BPC-1 Drug Profile | 414 | 1 |
buparlisib hydrochloride Drug Profile | 415 | 5 |
BXQ-350 Drug Profile | 420 | 2 |
cabazitaxel Drug Profile | 422 | 2 |
cabazitaxel Drug Profile | 424 | 1 |
cabiralizumab Drug Profile | 425 | 3 |
capmatinib Drug Profile | 428 | 3 |
CB-1158 Drug Profile | 431 | 2 |
CBL-0137 Drug Profile | 433 | 4 |
CBX-1 Drug Profile | 437 | 1 |
CCP-040 Drug Profile | 438 | 1 |
CCT-244747 Drug Profile | 439 | 2 |
CCV-3612552 Drug Profile | 441 | 1 |
Cellular Immunotherapy for HPV Associated Cancers Drug Profile | 442 | 1 |
Cellular Immunotherapy for Multiple Sclerosis Drug Profile | 443 | 1 |
Cellular Immunotherapy for Nasopharyngeal Cancer Drug Profile | 444 | 1 |
Cellular Immunotherapy for Oncology Drug Profile | 445 | 3 |